Table 1.

Previous reports of treatment with BRAF and/or MEK inhibitors in conjunctival melanoma patients.

References	Disease sites	Drug	Duration	Side effects	Outcome
Pahlitzsch et al. (19)	Local disease	Vemurafenib (not specified dose)	16 months	Weight loss, nausea and vomiting, headaches	Local control
Pinto Torres et al. (20)	Local recurrent disease	Vemurafenib (960 mg twice a day, reduced to 480 mg twice a day due to toxicity)	34 months	Grade 2 diarrhea, grade 2 arthralgia, grade 1 skin rash, needing a dose reduction	Complete response
Maleka et al. (21)	Pre-treated metastatic disease	Vemurafenib (960 mg twice a day, reduced to 720 mg twice a day due to toxicity)	4 months	Grade 2 maculopapular rash, needing a dose reduction	Partial response
Griewank et al. (22)	Pre-treated metastatic disease	Dabrafenib (150 mg twice a day)	6 months	[Not reported]	Partial response
Dagi Glass et al. (23)	Locally advanced disease	Dabrafenib and Trametinib interrupted for toxicity	1.5 months	Nausea and vomiting, leading to therapy discontinuation	Patient followed for over 23 mo without distant spread
		Vemurafenib	3.5 months	[Not reported]
		Pembrolizumab	2 months
		Vemurafenib and Cobimetinib (added after 4 months).	Not reported	[Not reported]